What subsequent therapies did patients receive after progressing on pirtobrutinib in the mantle cell BRUIN trial population?
Should pirtobrutinib be viewed as a bridge to CAR-T or transplant or a destination therapy?
Community PollStarted
When starting pirtobrutinib after prior BTKi in mantle cell lymphoma, for how long do you typically use it?
20 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Ohio State University James Cancer Center
Answered on
Not all post-protocol therapy was reported; however, nearly 20% of patients who were treated with pirtobrutinib on trial went on to receive CAR-T therapy. Pirtobrutinib’s ideal use is dependent on patient and disease characteristics. In the BRUIN trial, the median PFS, DOR, and OS of MCL patients wa...
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · Medical College of Wisconsin
Answered on
There is limited data on the outcomes of patients following pirtobrutinib but clinically, we have used this drug as a bridge to CAR-T in younger healthier patients, and for older frailer patients, we have used this drug until progression. With a rapidly evolving landscape in MCL, the role of these a...
Join for free or sign in to see the full answer